Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ZYTIGA is substantial. |
Clinical Added Value
| moderate |
ZYTIGA provides a moderate improvement in actual benefit (level III) in terms of efficacy and tolerance in the treatment of metastatic castration-resistant prostate cancer which progresses during or after docetaxel therapy. |
eNq1mF1v2jAUhu/5FVHuSQgdbZkC1cbaDanVGC3atJvKJIdiltrpsc3Hfv0cQjWYHHU4+DK2854Tn9ePjxJfrZ8zbwkoKGc9Pwpavgcs4SllTz1/8nDTvPSv+o14QZZkb9lF0Aqitu8lGRGi5xezwRQIE8GPu9tPoN8H9PsNL+bTBSTyYJ2SNAu+EDG/I3mxxouXnKbeM8g5T3t+ruR21IuFRJ1Ff8Xxl8hJAnG4G9mfXTy+2x+Pw0LsP1SVALwl7MkoCsxKM1GIwOSASHjiuKnI98xKm4oxCK4wgRGR8xHyJU0hNYaYkUyAVZDZKr0HXGYgiyBG8XCRPAsrcbIg6zG8DM1Jf9CzA7mWzVYzurhodTvd80738qxtFQr3tspcBf0RYfIYtc+iTrdlWZARR0kyR6WgYnDoJkdxEF7eLHlKRZ6RTbAQue1WESR6GlCfeXcfUnzBA2oKZXrP/tFnKsvCI7Oe7BjhKOMCQQOumKxAxc3YdiMGnElYV1fUjm5yvfMiBXE62d+cmck+UtOMJrYc06RRIORkPKzGWG0CfCQCJugOAd8pS/lKnB4t+6V0lH2+paNRNMc0emx3L8+jTsf65PzUvqm4S64V8hxCDR0q6rBkyGa8LkW0Fc1Sr0as58FtG8MTkkFFI9O0pIg232vf5cze7o5OOWEU/Xz9YOuJbwpwc799NErTtFevmokLbmsHViZ+vJ/LY+2kxVVoxsVcyly8D8PVahXMiWgKoncpmOFpGL53V7rrqp1cyGWDUnLQUerT8oI7riy2x+utK7tuG7p7f9fuGmNIVFCjFiWJnfFyeH16BP/tQZ2lPTpAhrsw236RSMqZq5ZGTY2KdRE0ZDeoAfF1NqMVfzkqfRmH5R+WfiMOi78r/cYfFGDUFw==
aPenSgc1FPKtucXS
Listen
